Oral Treosulfan as Second-Line Treatment in Platinum-Resistant Ovarian Cancer: A Phase II Study

By Keldsen N.   Madsen E.L.   Havsteen H.   Kamby C.   Laursen L.   Sandberg E.   on behalf of The Danish Ovarian Cancer Study Group  

Gynecologic Oncology, Vol. 69, Iss. 2, 1998-05 ,pp. : 100-102

Elsevier

Access to resources Recommend Favorite

Second-Line Therapy for Potentially Platinum-Sensitive Recurrent Ovarian Cancer: What Is Optimal Treatment?

By Markman M.  

Gynecologic Oncology, Vol. 81, Iss. 1, 2001-04 ,pp. : 1-2

Elsevier

Access to resources Recommend Favorite

Carboplatin Alone vs Carboplatin plus Epidoxorubicin as Second-Line Therapy for Cisplatin- or Carboplatin-Sensitive Ovarian Cancer

By Bolis G.   Scarfone G.   Giardina G.   Villa A.   Mangili G.   Melpignano M.   Presti M.   Tateo S.   Franchi M.   Parazzini F.   on behalf of the Associazione per la Ricerca in Ginecologia Oncologica ARGO 96 Study Group  

Gynecologic Oncology, Vol. 81, Iss. 1, 2001-04 ,pp. : 3-9

Elsevier

Access to resources Recommend Favorite

Second-Line Therapy of Ovarian Cancer with Paclitaxel Administered by Both the Intravenous and Intraperitoneal Routes: Rationale and Case Reports

By Markman M.   Kulp B.   Peterson G.   Kennedy A.   Belinson J.  

Gynecologic Oncology, Vol. 86, Iss. 1, 2002-07 ,pp. : 95-98

Academic Press

Access to resources Recommend Favorite

Paclitaxel vs Epidoxorubicin plus Paclitaxel as Second-Line Therapy for Platinum-Refractory and -Resistant Ovarian Cancer

By Bolis G.   Parazzini F.   Scarfone G.   Villa A.   Amoroso M.   Rabaiotti E.   Polatti A.   Reina S.   Pirletti E.  

Gynecologic Oncology, Vol. 72, Iss. 1, 1999-01 ,pp. : 60-64

Elsevier

Access to resources Recommend Favorite